Showing results (11-20 of 84) with videos related to
Sort By:
Pageof 9
Journal of Managed Care & Specialty Pharmacy|February 28, 2025
Use of health technology assessments in specialty drug coverage decisions by US commercial health plansDaniel E Enright, Emma G van Duijnhoven, Daniel A Ollendorf, et al.Journal of Medical Economics|September 20, 2021
Variation in access to hemophilia A treatments in the United StatesNikoletta M Margaretos, Anisha M Patel, Ari D Panzer, et al.The American Journal of Managed Care|April 14, 2022
Patients' access to 2018 FDA-approved drugs 1 year post approvalAri D Panzer, Nikoletta M Margaretos, Naomi Bridger, et al.Journal of Managed Care & Specialty Pharmacy|June 5, 2023
Specialty drug coverage varies between health plans' medical and pharmacy benefit policiesA Alex Levine, Ari D Panzer, Teresa L Kauf, et al.Applied Health Economics and Health Policy|September 3, 2024
Are Drug Novelty Characteristics Associated With Greater Health Benefits?A Alex Levine, Daniel E Enright, Katherine A Clifford, et al.Health Affairs (Project Hope)|November 4, 2024
Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower CostsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2024
The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan DrugsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.Journal of Managed Care & Specialty Pharmacy|August 31, 2021
Variation in health plan coverage of ESAs for anemia due to chronic kidney diseaseNikoLetta M Margaretos, Ari D Panzer, Rachel C Lai, et al.Health Affairs Scholar|May 17, 2024
Commercial coverage of specialty drugs, 2017-2021Julia A Rucker, Molly T Beinfeld, Nola B Jenkins, et al.Health Affairs Scholar|February 25, 2026
The timeliness of health plan drug coverage policy changes to FDA label revisionsDaniel E Enright, Molly T Beinfeld, Claire H Brennan, et al.Pageof 9